Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre, open-label, phase 1a dose-escalation study

Authors

Fiona Thistlethwaite (ORCID: https://orcid.org/0000-0002-4832-7008)
Wenshu Lu (ORCID: https://orcid.org/0000-0002-4857-843X)
Shisong Jiang (ORCID: https://orcid.org/0000-0003-2103-6929)
Martin D. Forster
Wynne Wijaya
Anja Williams
Michael Flynn
Mark Tuthill
Thomas Morris
William Finch

Institutions

University College Hospital (GB)
University College London Hospitals NHS Foundation Trust (GB)
Sarah Cannon Research Institute (GB)
University of Oxford (GB)
The Christie NHS Foundation Trust (GB)
Oxford University Hospitals NHS Trust (GB)
University College London (GB)

Publication Details

Journal: EClinicalMedicine
Published: 2025-12-27
DOI: https://doi.org/10.1016/j.eclinm.2025.103717
Primary Topic: Immunotherapy and Immune Responses
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre, open-label, phase 1a dose-escalation study

Fiona Thistlethwaite, Wenshu Lu, Shisong Jiang, Martin D. Forster et al.

Dec 27, 2025

EClinicalMedicine

Immunotherapy and Immune Responses

article

Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre, open-label, phase 1a dose-escalation study

Fiona Thistlethwaite, Wenshu Lu, Shisong Jiang, Martin D. Forster, Wynne Wijaya, Anja Williams, Michael Flynn, Mark Tuthill, Thomas Morris, William Finch

December 27, 2025article en

Abstract

No abstract available for this paper.

EClinicalMedicineVol. 91

University College Hospital (GB), University College London Hospitals NHS Foundation Trust (GB), Sarah Cannon Research Institute (GB), University of Oxford (GB), The Christie NHS Foundation Trust (GB), Oxford University Hospitals NHS Trust (GB), University College London (GB)

Good health and well-being

Openalex Percentile: Top 36%

Immunotherapy and Immune Responses

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre, open-label, phase 1a dose-escalation study — Fiona Thistlethwaite, Wenshu Lu, et al. · EClinicalMedicine (2025) | TGRS Research Map | TGRS